Jump to content

Ginkgo Bioworks

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Scottjohnson27 (talk | contribs) at 19:33, 15 May 2021 (add recent info about ticker symbol). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Ginkgo Bioworks
Company typePrivate
IndustryBiotechnology
Founded2009; 16 years ago (2009) in Boston, Massachusetts, United States of America
FoundersTom Knight, Jason Kelly, Reshma Shetty, Barry Canton, Austin Che
Headquarters,
Key people
Tom Knight
Jason Kelly
Reshma Shetty
Barry Canton
Austin Che
Christina Agapakis, Creative Director
Number of employees
~600
Websiteginkgobioworks.com

Ginkgo Bioworks is a biotech company from the United States founded in 2009 by scientists from MIT and headed by Tom Knight. The company specializes in using genetic engineering to produce bacteria with industrial applications.[1][2][3][4] Ginkgo Bioworks is an analytics company that designs organisms for customers in a range of industries. It is the self-proclaimed "Organism Company" and is one of the world's largest privately held biotech companies.[5] As of 2019, it was valued at $4.2 billion.[6]

On 11 May 2021, Gingko Bioworks announced plans of going public through a merger with SPAC Soaring Eagle at a $17.5 billion valuation.[7]

On 14 May 2021, Ginkgo announced it's new ticker for the NYSE will be DNA. THe ticker was previously used by Genentech, who stopped using the ticker after they were acquired by Roche.

Funding

In 2019, Ginkgo Bioworks received $290 million in September and a $350 million fund in October. [5]

References

  1. ^ Molteni, Megan (14 September 2017). "With Designer Bacteria, Crops One Day Could Fertilize Themselves". Wired. Retrieved 4 December 2017.
  2. ^ Herper, Mathew (8 June 2016). "Boston Startup Raises $100 Million To Use Synthetic Biology To Design Microbes For Industry". Forbes. Retrieved 4 December 2017.
  3. ^ Adams, Susan (14 September 2017). "Bayer And Ginkgo Bioworks, A Startup, Aim To Make Crops Produce Their Own Nitrogen Fertilizer". Forbes. Retrieved 4 December 2017.
  4. ^ Weisman, Robert (29 September 2016). "Ginkgo Bioworks opens production site for custom cells". Boston Globe. Retrieved 4 December 2017.
  5. ^ a b "Ginkgo Bioworks raises $350 million fund for biotech spinouts". Reuters. 2019-10-09. Retrieved 2019-11-07.
  6. ^ "Ginkgo Bioworks CEO Wants Biology to Manufacture Physical Goods". Bloomberg. Retrieved 2019-11-07.
  7. ^ Hussain, Niket Nishant, Noor Zainab (2021-05-11). "Biotech firm Ginkgo to merge with Harry Sloan-led SPAC in $17.5 billion deal". Reuters. Retrieved 2021-05-12.{{cite news}}: CS1 maint: multiple names: authors list (link)